Treatment of Motor Fluctuations in Parkinson's Disease

Motor fluctuations are a recognised challenge in Parkinson's disease management. When a patient experiences wearing-off or unpredictable on-off phenomena, the treatment strategy requires careful adjustment of the existing regimen.

Clinical scenario This protocol addresses Parkinson's disease in patients with motor response fluctuations — a situation requiring a structured, stepwise pharmacological approach to re-establish consistent symptom control.

Treatment approach (partial overview)

The approach to fluctuations involves modifications to dopaminergic therapy — including adjustments to Levodopa dosing schedules and the possible addition of agents from other pharmacological classes such as dopamine agonists, MAO-B inhibitors, or COMT inhibitors. Specific agents and their sequencing depend on individual patient factors.

Full regimen — including agent selection criteria, sequencing, safety monitoring, and contraindications — is available in the complete structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1186/s42466-024-00325-4

Various medication options are available for treating fluctuations, including adjusting Levodopa intervals and dosages, additional administration of Levodopa preparations with modified galenic forms (soluble, inhaled, retarded), or adding dopamine agonists, MAO-B inhibitors, or COMT inhibitors.

Opicapone and Entacapone are largely equivalent in effect as COMT inhibitors and can be used for treating Levodopa-response fluctuations in PD, considering specific indications outlined below.

Tolcapone should be used cautiously due to potential hepatotoxicity, primarily as a second-line treatment with rigorous clinical and laboratory safety monitoring.

Safinamide, a dual-action MAO-B inhibitor, is not approved as monotherapy but can be used in combination with Levodopa for treating PD with fluctuations.

View source ↗